Available evidence comparing calcitonin gene-related peptide (CGRP) receptor antagonists is largely derived from meta-analyses and indirect comparisons rather than direct head-to-head randomized trials. However, data from these analyses consistently demonstrate that both gepants (e.g., rimegepant, ubrogepant, zavegepant) for acute treatment and monoclonal antibodies (e.g., erenumab, fremanezumab, galcanezumab, eptinezumab) for prevention are superior to placebo, with generally similar efficac...
A 2024 systematic review and network meta analysis (NMA) of 18 randomized controlled trials (RCTs) including 22,429 patients compared Lasmiditan, Rimegepant, Ubrogepant, and Zavegepant for acute migraine treatment. All agents were superior to placebo. For pain freedom at 2 hours, lasmiditan 100 mg (risk ratio [RR] 1.54; 95% confidence interval [CI] 1.21 to 1.99), lasmiditan 200 mg (RR 1.85; CI 1.46 to 2.40), rimegepant 75 mg (RR 1.82; CI 1.30 to 2.55), and ubrogepant 25 to 100 mg were all effective, with ubrogepant 100 mg ranking highest. For pain relief at 2 hours, lasmiditan 100 mg (RR 1.44; CI 1.34 to 1.55) and 200 mg (RR 1.43; CI 1.33 to 1.54) ranked highest and were superior to lower dose ubrogepant and zavegepant. For most bothersome symptom freedom at 2 hours, rimegepant 75 mg (RR 1.40, CI 1.17 to 1.68) and ubrogepant 50 mg (RR 1.40; CI 1.11 to 1.78) ranked highest. For sustained pain relief at 24 hours, all gepants were effective, including rimegepant, ubrogepant 25 to 100 m...
READ MORE→
A search of the published medical literature revealed
1 study investigating the researchable question:
Is there literature comparing efficacy and safety between the CGRP Receptor Antagonists?
Level of evidence
C - Multiple studies with limitations or conflicting results
READ MORE→
[1] Deng X, Zhou L, Liang C, et al. Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials. J Headache Pain. 2024;25(1):16. Published 2024 Feb 5. doi:10.1186/s10194-024-01723-4
[2] Haridas MP, Tripathy A, Maiti R, Srinivasan A. Efficacy and safety of anti-cgrp monoclonal antibodies in prevention of chronic migraine: a bayesian network meta-analysis. Clin Psychopharmacol Neurosci. 2024;22(1):23-32. doi:10.9758/cpn.23.1109
[3] Asawavichienjinda T, Sathitratanacheewin S, Chokesuwattanaskul R. "Wearing-off" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials. Cephalalgia. 2023;43(4):3331024231161261. doi:10.1177/03331024231161261
[4] Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023;43(4):3331024231159366. doi:10.1177/03331024231159366
[5] Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia. 2023;43(3):3331024231152169. doi:10.1177/03331024231152169
[6] Lee S, Staatz CE, Han N, Baek IH. Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2022;78(9):1365-1376. doi:10.1007/s00228-022-03347-6
[7] Masoud AT, Hasan MT, Sayed A, et al. Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials. J Neurol Sci. 2021;427:117505. doi:10.1016/j.jns.2021.117505
[8] Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score. CNS Drugs. 2022;36(2):191-202. doi:10.1007/s40263-021-00893-y